We welcome the report and commend the progress. Substandard and falsified medical products continue to threaten public health, especially for cancer patients. Several widely used cancer medicines have been found to fall short of essential quality assessments.

We urge Member States to:
* Support sustainable financing for the implementation of the Member State mechanism on substandard and falsified medical products
* Strengthen national regulatory authorities, including laboratory capacity and risk-based market surveillance, including tools like Epione, alongside improved data sharing with the Global Surveillance and Monitoring System to improve reporting and reduce duplication
* Prioritise strong communication strategies and drive coordinated cross-sector action against online and informal market distribution
* Reinforce supply chain oversight and data sharing, including high-risk raw materials.